Research Analysts Offer Predictions for Liquidia Q1 Earnings

Liquidia Co. (NASDAQ:LQDA) – Research analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for Liquidia in a research note issued on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville expects that the company will post earnings of ($0.37) per share for the quarter. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million.

Several other brokerages also recently weighed in on LQDA. Needham & Company LLC increased their target price on shares of Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Wells Fargo & Company began coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Scotiabank lifted their target price on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research note on Thursday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Liquidia presently has an average rating of “Buy” and a consensus target price of $26.63.

Liquidia Stock Performance

Shares of Liquidia stock opened at $15.12 on Friday. The company has a market capitalization of $1.28 billion, a P/E ratio of -9.28 and a beta of 0.07. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.92. The company’s fifty day moving average is $14.79 and its two-hundred day moving average is $12.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Liquidia by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock worth $41,834,000 after purchasing an additional 115,367 shares during the last quarter. LM Advisors LLC acquired a new position in shares of Liquidia during the 4th quarter valued at about $25,948,000. Whitefort Capital Management LP increased its position in Liquidia by 16.8% during the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock worth $23,370,000 after purchasing an additional 285,220 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Liquidia by 17.3% during the 4th quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company’s stock worth $20,698,000 after buying an additional 260,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Liquidia by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock worth $15,753,000 after acquiring an additional 101,597 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Transactions at Liquidia

In other news, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the transaction, the insider now directly owns 270,388 shares of the company’s stock, valued at $3,185,170.64. This represents a 2.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Russell Schundler sold 16,393 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the sale, the general counsel now owns 573,478 shares of the company’s stock, valued at $6,755,570.84. This trade represents a 2.78 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 71,245 shares of company stock valued at $843,326. Corporate insiders own 30.10% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).